Want to see KYMR full AI Analyst Report?
Total Valuation
Kymera Therapeutics has a market cap or net worth of $9.76B. The enterprise value is $10.65K.
Market Cap$9.76B
Enterprise Value$10.65K
Share Statistics
Kymera Therapeutics has 83,150,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83,150,620
Owned by Insiders11.97%
Owned by Institutions12.34%
Financial Efficiency
Kymera Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.88%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-20.88%
Return on Capital Employed (ROCE)-0.21
Revenue Per Employee143.59K
Profits Per Employee-1.14M
Employee Count273
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kymera Therapeutics is ―. Kymera Therapeutics’s PEG ratio is -0.89.
PE Ratio―
PS Ratio167.51
PB Ratio4.16
Price to Fair Value4.16
Price to FCF-28.02
Price to Operating Cash Flow-48.68
PEG Ratio-0.89
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 39.20M and earned -311.40M in profits. Earnings per share was -3.69.
Revenue39.20M
Gross Profit39.20M
Operating Income-349.40M
Pretax Income-311.62M
Net Income-311.40M
EBITDA-303.06M
Earnings Per Share (EPS)-3.69
Cash Flow
In the last 12 months, operating cash flow was -236.76M and capital expenditures -1.19M, giving a free cash flow of -237.96M billion.
Operating Cash Flow-236.76M
Free Cash Flow-237.96M
Free Cash Flow per Share-2.86
Dividends & Yields
Kymera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.79
52-Week Price Change169.12%
50-Day Moving Average104.06
200-Day Moving Average84.64
Relative Strength Index (RSI)65.24
Average Volume (3m)1.05M
Important Dates
Kymera Therapeutics upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Kymera Therapeutics as a current ratio of 10.47, with Debt / Equity ratio of 5.45%
Current Ratio10.47
Quick Ratio10.47
Debt to Market Cap<0.01
Net Debt to EBITDA0.91
Interest Coverage Ratio-1.40K
Taxes
In the past 12 months, Kymera Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kymera Therapeutics EV to EBITDA ratio is -20.76, with an EV/FCF ratio of -26.85.
EV to Sales160.50
EV to EBITDA-20.76
EV to Free Cash Flow-26.85
EV to Operating Cash Flow-27.02
Balance Sheet
Kymera Therapeutics has $690.99M in cash and marketable securities with $82.22M in debt, giving a net cash position of $608.76M billion.
Cash & Marketable Securities$690.99M
Total Debt$82.22M
Net Cash$608.76M
Net Cash Per Share$7.32
Tangible Book Value Per Share$18.72
Margins
Gross margin is 101.98%, with operating margin of -891.33%, and net profit margin of -794.39%.
Gross Margin101.98%
Operating Margin-891.33%
Pretax Margin-794.96%
Net Profit Margin-794.39%
EBITDA Margin-773.11%
EBIT Margin-794.32%
Analyst Forecast
The average price target for Kymera Therapeutics is $131.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$131.33
Price Target Upside18.78% Upside
Analyst ConsensusStrong Buy
Analyst Count18
Revenue Growth Forecast134.84%
EPS Growth Forecast6.73%